APA (7th ed.) Citation

MR, H., M, T., OA, C., GR, T., MA, S., JA, M., . . . R, P. (2025). Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 81(5), e302. https://doi.org/10.1093/cid/ciaf185

Chicago Style (17th ed.) Citation

MR, Hodges, et al. "Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 81, no. 5 (2025): e302. https://doi.org/10.1093/cid/ciaf185.

MLA (9th ed.) Citation

MR, Hodges, et al. "Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 81, no. 5, 2025, p. e302, https://doi.org/10.1093/cid/ciaf185.